CO*RE 2024-2025 CURRICULUM ON PAIN MANAGEMENT

The CO*RE 2024-2025 curriculum, created by renowned pain management and addiction experts addresses pain pathophysiology, patient assessment, patient-centered treatment plans, non-pharmaceutical options, opioid management, patient education, and opioid use disorder.

This program meets many states’ requirements for pain education and is fully compliant with the Opioid Analgesic Risk Evaluation and Mitigation Strategy (REMS) education requirement (“Blueprint”), issued by the U.S. Food & Drug Administration. Additionally this education may be used to satisfy, in part, requirements of the MATE Act, as noted in SAMHSA Recommendations for Curricular Elements in Substance Use Disorder.

This education can be delivered at your next conference or meeting. Please email JerriDavis@core-rems.org for additional information. You can select a course option that fits the needs of your audience. We offer two types of curriculum for live or online education, and an online podcast.

CO*RE Didactic Curriculum
Our didactic learning session is designed to provide a comprehensive and structured approach to pain management education. This session meticulously follows the FDA Blueprint, ensuring that participants receive the most up-to-date and evidence-based knowledge.

CO*RE Case-Based Curriculum
Our case-based session delivers a real-world educational experience through a series of cases and supporting content mapped to the FDA Blueprint. This allows faculty to teach application of concepts, fostering an engaging approach to pain management education.

CO*RE Podcast Developed by ASAM
This series features three 45-minute podcasts aimed at empowering clinicians to manage pain confidently. The series also follows the FDA Blueprint, covering patient assessment, treatment plan creation, therapy initiation, modification, discontinuation, and patient counseling.

RESULTS

Since 2013, CO*RE has delivered in-person and online education to more than 452,000 clinicians via more than 700 CE/CME activities (through December 2022).

CO*RE uses a Common Outcomes Framework to align the FDA Blueprint with CO*RE learning objectives, content, and assessment questions. This makes for consistency across courses and allows for more robust data analysis on educational impact.

CO*RE learner data is compiled in a custom dashboard, which allows us to identify patterns and look for additional gaps to be addressed. For example, here are key learnings from our 2019 Outcomes Report:

  • Learners at in-person live activities scored higher on posttests than learners in online activities
  • Learners with individual DEA registration scored higher than those with institutional DEA or none
  • Learners in our Adaptive Learning course demonstrated 36% improvement in confidence in opioid rotation and in using the ORT OUD
  • Learners reported making more changes after the education than they had planned (see figure)
CO*RE is launching a new series of 45 educational programs in 2022-2023

CO*RE is launching a new series of 45 educational programs in 2022-2023, and will continue with our robust data analysis.

TESTIMONIALS

Here’s what people have to say about their experience:

“I like the videos of other healthcare providers having the difficult conversation with a patient – good modeling!”

– Physician

“One of the best activities of this sort I’ve seen.”

– Physician

“I was so encouraged by what I heard that I intend to overcome my own discouragement and make time to work this into my treatment of pain patients. I will re-evaluate my decision to stop treating chronic pain.”

– New Mexico Clinician

“The best CE I have completed so far. Thank you. Very clear but also very thorough – which is a tough balance to achieve. Thanks!”

– Nurse Practitioner

FUNDER INFORMATION

This educational activity is supported by an independent educational grant from the Opioid Analgesic REMS Program Companies (RPC). This activity is intended to be fully compliant with the Opioid Analgesic REMS education requirements issued by the U.S. Food and Drug Administration. Click here for more information about the Opioid Analgesics REMS.